Eliem Therapeutics Long Term Debt

Eliem Therapeutics (ELYM) currently reports a long-term debt of $810K as of June 2026. That compares with $420K in the prior-year period — up 95.0% year over year. Use the charts on this page to explore Eliem Therapeutics's long-term debt history and peer comparisons.

Eliem Therapeutics's long-term debt increased from $420K to $810K — a 95.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eliem Therapeutics reported $810K in long-term debt as of June 2026. That compares with $420K in the prior-year period — up 95.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $810K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Eliem Therapeutics, and consider following ELYM for alerts when major investors trade the stock.

Eliem Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $810K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ELYM with unrelated industries.